FOSUN PHARMA (02196) surged nearly 4% during the trading session. At the time of writing, the stock was up 3.76% to HK$23.16, with a turnover of HK$50.41 million.

The company recently announced its financial results for the nine months ended September 30, 2025. The group reported revenue of RMB29.39 billion, a year-on-year decrease of 4.91%. However, net profit attributable to shareholders rose 25.5% YoY to RMB2.52 billion, with basic earnings per share at RMB0.95.

The increase in total profit, net profit attributable to shareholders, and basic/diluted EPS was primarily driven by gains from the divestment of remaining equity in United Family Healthcare and other non-core assets.

Guotai Junan Securities noted that FOSUN PHARMA continued to advance its innovative product pipeline in Q3 2025. In September, its novel small-molecule CDK4/6 inhibitor FCN-437c secured approval for an additional indication in China. HLX14 (denosumab biosimilar) received approvals for launch in both the U.S. and EU markets during the same month. Additionally, FKC889 (brexucabtagene autoleucel injection) has submitted its domestic marketing application, which was accepted by China's NMPA in September. The brokerage believes the sequential launch of these innovative drugs will drive revenue recovery.